NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: DIVISLAB · data 2026-10-30
Divi's Laboratories Limited
In plain words
Price: at or near its 52-week high.
Delivery: 60.8% of traded shares were kept for delivery over the last 10 sessions, against 61.8% over the last 60.
Latest results: a net profit of ₹583 cr for the quarter ended Dec 2025.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹11,230 cr |
| Net profit (last 12 months) | ₹2,925 cr |
| Sales growth, 3 years (yearly) | 10.8% |
| Profit growth, 3 years (yearly) | 12.1% |
Latest results in brief (Q3 FY26)
DIVISLAB Q3 FY26 results (consolidated figures, as filed on NSE).
Revenue was ₹2,604 crore.
Net profit was ₹583 crore.
Operating margin was 34.2%.
EPS was ₹21.98.
DIVISLAB के Q3 FY26 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹2,604 करोड़।
शुद्ध मुनाफ़ा: ₹583 करोड़।
ऑपरेटिंग मार्जिन: 34.2%।
EPS: ₹21.98।
DIVISLABના Q3 FY26 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹2,604 કરોડ.
ચોખ્ખો નફો: ₹583 કરોડ.
ઓપરેટિંગ માર્જિન: 34.2%.
EPS: ₹21.98.
Written from the filed numbers. Not a recommendation.
Smart-money activity
39/100 · Neutral over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 6/30: Delivery 62.8% over the last 20 sessions vs 61.5% in the 40 before (1.02x); shares delivered per day 1.37x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 15/15: 66 schemes hold it, about ₹13,833 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 13/15: Verdict "Sustained", sustained score 71/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Dividend
- 1 Aug 26Results Results board meeting +6.6% next session
- 24 Jul 26Dividend Dividend ₹30 (ex-date) +1.5% next session
- 23 May 26Results Results board meeting -1.9% next session
- 11 Feb 26Results Q3 FY26 results: net profit ₹583 cr +0.2% next session
- 7 Nov 25Results Results board meeting -2.8% next session
- 6 Aug 25Results Results board meeting -4.3% next session
- 25 Jul 25Dividend Dividend ₹30 (ex-date) -0.5% next session
- 17 May 25Results Q4 FY25 results: net profit ₹662 cr +4.8% next session
- 3 Feb 25Results Results board meeting +8.5% next session
- 9 Nov 24Results Results board meeting -0.8% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Dec 2025 | ₹2,604 cr | ₹583 cr | — | 34.2% | 21.98 |
| Mar 2025 | ₹2,585 cr | ₹662 cr | — | 34.3% | 24.93 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2024 |
|---|---|---|---|---|
| Promoters | 51.88% | 51.88% | 51.88% | 51.89% |
| Foreign institutions (FII) | 20.38% | 20.20% | 20.29% | 17.99% |
| Domestic institutions (DII) | 19.17% | 19.38% | 19.22% | 20.54% |
| Mutual funds | 14.66% | 13.87% | 13.42% | 11.89% |
| Retail investors | 6.11% | 5.93% | 5.99% | 6.84% |
| Number of shareholders | 2,32,256 | 2,26,324 | 2,28,006 | 2,80,601 |
Common questions
What was Divi's Laboratories Limited's latest quarterly profit?
Divi's Laboratories Limited reported a net profit of ₹583 cr for the quarter ended Dec 2025, on revenue of ₹2,604 cr.
How much do promoters hold in Divi's Laboratories Limited?
Promoters held 51.88% of Divi's Laboratories Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Divi's Laboratories Limited debt-free?
Its latest reported debt-to-equity ratio is 0, so it carries little or no borrowing on the balance sheet.
What is Divi's Laboratories Limited's P/E ratio?
About 88.8, based on the last 12 months' earnings and a price of ₹9,780 (data 2026-10-30).
What is the 52-week high and low of Divi's Laboratories Limited?
The 52-week high is ₹9,865 and the 52-week low is ₹5,647.5.
Mutual funds holding Divi's Laboratories Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 66 schemes holding about ₹13,833 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| SBI Large Cap Fund | SBI Mutual Fund | 3.61% | ₹1,891 cr |
| SBI Aggressive Hybrid Fund | SBI Mutual Fund | 1.83% | ₹1,577 cr |
| SBI Focused Fund | SBI Mutual Fund | 2.41% | ₹1,209 cr |
| SBI MultiCap Fund | SBI Mutual Fund | 3.37% | ₹791 cr |
| SBI Large and Midcap Fund | SBI Mutual Fund | 1.90% | ₹770 cr |
| NIPPON INDIA LARGE CAP FUND | Nippon India Mutual Fund | 1.45% | ₹744 cr |
| Mirae Asset Large & Midcap Fund | Mirae Asset Mutual Fund | 1.52% | ₹651 cr |
| NIPPON INDIA PHARMA FUND | Nippon India Mutual Fund | 7.10% | ₹651 cr |
| Nippon India Multi Cap Fund | Nippon India Mutual Fund | 1.15% | ₹618 cr |
| SBI Healthcare Opportunities Fund | SBI Mutual Fund | 7.91% | ₹464 cr |
| NIPPON INDIA ETF NIFTY NEXT 50 JUNIOR BEES | Nippon India Mutual Fund | 4.84% | ₹419 cr |
| SBI MNC Fund | SBI Mutual Fund | 5.82% | ₹371 cr |
| Mirae Asset ELSS Tax Saver Fund | Mirae Asset Mutual Fund | 1.48% | ₹364 cr |
| Nippon India ELSS Tax Saver Fund | Nippon India Mutual Fund | 2.44% | ₹344 cr |
| Mirae Asset Healthcare Fund | Mirae Asset Mutual Fund | 9.79% | ₹342 cr |
Similar companies
Sun Pharmaceutical Industries Limited (SUNPHARMA) · Torrent Pharmaceuticals Ltd (TORNTPHARM) · Laurus Labs Ltd. (LAURUSLABS) · Zydus Lifesciences Limited (ZYDUSLIFE) · Dr. Reddy's Laboratories Ltd. (DRREDDY)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open DIVISLAB in NSE Scanner →